Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in Chronic Spontaneous Urticaria
NCT07838727Phase 2Not yet recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Sep 2026
- Primary completion
- May 2027
01
Overview
A Phase 2 trial of comekibart in chronic spontaneous urticaria (CSU), sponsored by Hunan Mabgeek Biotechnology. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
comekibart
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07838727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838727.